|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO008067341 |
| 003 |
DE-627 |
| 005 |
20230425183204.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
211221s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO008067341
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)IRCT20210913052453N1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a The chelating effect of zinc in patients with Covid 19
|b Administration of Zinc-Chelating Agents (intravenuosly CaNa2EDTA) in COVID-19 Patients: A pilot study
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-11-08, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Condition 1: covid-19. Condition 2: covid-19. Condition 3: covid-19. Condition 4: covid-19. Coronavirus infection, unspecified Dyspnea Cough Pneumonia due to SARS-associated coronavirus;B34.2;R06.0;J12.81
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2/Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Completed
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 29. Nov.
|
| 773 |
1 |
8 |
|g year:2021
|g day:29
|g month:11
|
| 856 |
4 |
0 |
|u http://en.irct.ir/trial/58675
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 29
|c 11
|
Klinische Studie